Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY)

https://www.bavariannordic.com

Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe and Canada. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine. *

	Start	1999-04-01 existent
	Group	Bavarian Nordic (Group)
	Predecessor	Bavarian Nordic Research Institute A/S
	Industry	gene therapy

	Region	Denmark_oo
	Country	Denmark
	Street	9 Bogeslowej
	City	3490 Kvistgard
	Tel	+45-3326-8383
		Address record changed: 2024-01-05

Basic data	Employees	E: 501 to 1,000 (2022-12-31)
	Currency	DKK
	Annual sales	3,150,793,000 (revenue, consolidated (2022) 2022-12-31)
	Profit	-347,382,000 (2022-12-31)
	Cash	575,407,000 (2022-12-31)

		* Document for »About Section«: Bavarian Nordic A/S. (12/6/21). "Press Release: Bavarian Nordic A/S Announces Completion of Directed Issue of 6,373,680 New Ordinary Shares [Not for US, CA, JP, et al.]". Copenhagen.

		Record changed: 2024-08-12